Idexx Laboratories (IDXX) Non-Current Deffered Revenue (2009 - 2026)

Idexx Laboratories has reported Non-Current Deffered Revenue for 18 years, with the latest figure at $32.6 million in Q2 2026.

• On a quarterly basis, Non-Current Deffered Revenue rose 2.59% year-over-year to $32.6 million in Q2 2026; TTM through Jun 2026 was $32.6 million, a 2.59% increase from a year earlier, with the FY2025 full-year figure at $32.2 million, up 19.44% from the prior year.
• Non-Current Deffered Revenue was $32.6 million for Q2 2026 at Idexx Laboratories, up from $32.3 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $39.2 million in Q1 2022, with the low at $26.8 million in Q3 2024.
• Average Non-Current Deffered Revenue over 5 years is $30.7 million, with a median of $30.7 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Non-Current Deffered Revenue dropped 25.04% in 2022, then advanced 20.49% in 2026.
• Over 5 years, Non-Current Deffered Revenue stood at $30.9 million in 2022, then fell by 7.55% to $28.5 million in 2023, then retreated by 5.59% to $26.9 million in 2024, then increased by 19.44% to $32.2 million in 2025, then rose by 1.27% to $32.6 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $32.6 million (Q2 2026), $32.3 million (Q1 2026), and $32.2 million (Q4 2025), per Business Quant data.